Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study
Xiao-Fan Zhu,Hai-Long He,Shun-Qing Wang,Jing-Yan Tang,Bing Han,Dong-Hua Zhang,Li-Qiang Wu,De-Pei Wu,Wei Li,Ling-Hui Xia,Huan-Ling Zhu,Feng Liu,Hong-Xia Shi,Xi Zhang,Fang Zhou,Jian-Da Hu,Jian-Pei Fang,Xie-Qun Chen,Tie-Zhen Ye,Ying-Min Liang,Jie Jin,Feng-Kui Zhang
DOI: https://doi.org/10.1159/000499065
2019-01-01
Acta Haematologica
Abstract:Aplastic anemia (AA) is a hematologic disease characterized by pancytopenia and hypocellular bone marrow, potentially leading to chronic anemia, hemorrhage, and infection. The China Aplastic Anemia Committee and British Committee for Standards in Haematology guidelines recommend hematopoietic stem-cell transplantation (HSCT) or immunosuppressive therapy (IST) comprising antithymocyte globulin (ATG) with cyclosporine (CsA) as initial treatment for AA patients. With limited epidemiological data on the clinical management of AA in Asia, a prospective cohort registry study involving 22 AA treatment centers in China was conducted to describe the disease characteristics of newly diagnosed AA patients and investigate real-world treatment patterns and patient outcomes. Of 340 AA patients, 72.9, 12.6, and 3.5% were receiving IST, traditional Chinese medicine, and HSCT, respectively, at baseline; only 22.2% of IST-treated patients received guideline-recommended ATG with CsA initially. Almost all patients received supportive care (95.6%) as blood transfusion (97.8%), antibiotics (63.7%), and/or hematopoietic growth factors (58.2%). Overall, 64.8% achieved a partial or complete response, and 0.9% experienced relapse. No new safety concerns were identified; serious adverse events were largely unrelated to the treatment regimen. These results demonstrate the need to identify and minimize treatment barriers to standardize and align AA management in China with treatment guideline recommendations and further improve patient outcomes.